Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitri Iarikov

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The AIDS Reader|November 4, 2008
Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndromeDmitri Iarikov, Wayne Duke, Daniel Skiest
Infectious Diseases and Therapy|October 7, 2015
Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System DatabaseDmitri Iarikov, Ronald Wassel, John Farley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2014
Hypoglycemia in patients treated with linezolidPrabha Viswanathan, Dmitri Iarikov, Ronald Wassel, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2022
Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal ImpairmentLuning Zhuang, Kunyi Wu, Seong H Jang, et al.
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Emerging Infectious Diseases|October 24, 2024
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical NeedsMayurika Ghosh, Dmitri Iarikov, Xiaojing Karen Qi, et al.
The Journal of Infectious Diseases|March 19, 2024
Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in AdultsHeidi L Smith, Timothy J Bensman, Shrimant Mishra, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2020
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug DevelopmentJames M Byrne, Ursula Waack, Edward A Weinstein, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The AIDS Reader|November 4, 2008
Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndromeDmitri Iarikov, Wayne Duke, Daniel Skiest
Infectious Diseases and Therapy|October 7, 2015
Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System DatabaseDmitri Iarikov, Ronald Wassel, John Farley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2014
Hypoglycemia in patients treated with linezolidPrabha Viswanathan, Dmitri Iarikov, Ronald Wassel, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2022
Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal ImpairmentLuning Zhuang, Kunyi Wu, Seong H Jang, et al.
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Emerging Infectious Diseases|October 24, 2024
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical NeedsMayurika Ghosh, Dmitri Iarikov, Xiaojing Karen Qi, et al.
The Journal of Infectious Diseases|March 19, 2024
Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in AdultsHeidi L Smith, Timothy J Bensman, Shrimant Mishra, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2020
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug DevelopmentJames M Byrne, Ursula Waack, Edward A Weinstein, et al.
Pageof 1